https://v1.pharmanews.devmesh.eu/story/725170/novo-signs-up-to-1-3b Rxwire en 2026-09-25T07:11:15Z Novo signs up to $1.3B deal for Nanexa drug-delivery technology https://v1.pharmanews.devmesh.eu/story/725884/the-independent-pharmacy-opportunity-pharma-marketers Rxwire en 2026-09-25T10:00:00Z The independent pharmacy opportunity pharma marketers are overlooking https://v1.pharmanews.devmesh.eu/story/725880/mhra-approves-pharma-mar-s-lurbinectedin Rxwire en 2026-09-25T09:40:00Z MHRA approves Pharma Mar’s lurbinectedin for extensive-stage small cell lung cancer https://v1.pharmanews.devmesh.eu/story/725878/heard-on-the-street-there-is Rxwire en 2026-09-25T09:30:00Z Heard on the Street: There is areal opportunity for pill-form peptides to hit big pharma’s most profitable franchises https://v1.pharmanews.devmesh.eu/story/721906/u-s-food-and-drug-administration Rxwire en 2026-09-24T10:45:00Z U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes https://v1.pharmanews.devmesh.eu/story/725941/ona-therapeutics-moves-to-phase-i Rxwire en 2026-09-25T09:09:57Z Ona Therapeutics moves to Phase I with ADC for advanced cancers https://v1.pharmanews.devmesh.eu/story/725747/new-crispr-based-tool-enables-genome Rxwire en 2026-09-25T09:00:58Z New CRISPR-Based Tool Enables Genome-Wide Mutagenesis of Bacteriophages https://v1.pharmanews.devmesh.eu/story/725877/vilnius-university-develops-photoredox-method-to Rxwire en 2026-09-25T08:58:00Z Vilnius University develops photoredox method to accelerate drug discovery https://v1.pharmanews.devmesh.eu/story/725560/wnt-drug-gives-msd-first-eye Rxwire en 2026-09-25T08:40:34Z Wnt drug gives MSD first eye disease win after EyeBio deal https://v1.pharmanews.devmesh.eu/story/725508/how-big-tobacco-flooded-the-fda Rxwire en 2026-09-25T08:30:00Z How Big Tobacco flooded the FDA with public comments to kill a menthol cigarette ban https://v1.pharmanews.devmesh.eu/story/725559/ai-agents-target-drug-safety-protein Rxwire en 2026-09-25T08:25:00Z AI agents target drug safety, protein discovery and secure health data analysis https://v1.pharmanews.devmesh.eu/story/725369/theialife-s-race-to-bring-a Rxwire en 2026-09-25T08:00:00Z Theialife’s race to bring a childhood myopia treatment to market https://v1.pharmanews.devmesh.eu/story/725388/cryoport-strong-pipeline-of-cell-and Rxwire en 2026-09-25T07:26:56Z Cryoport: Strong Pipeline Of Cell And Gene Therapy Approvals https://v1.pharmanews.devmesh.eu/story/725115/which-control-system-is-best-for Rxwire en 2026-09-25T07:00:00Z Which control system is best for personalised medicine? https://v1.pharmanews.devmesh.eu/story/725828/indivior-ends-pam-drug-collab-with Rxwire en 2026-09-25T05:24:00Z Indivior ends PAM drug collab with Addex ahead of Supernus merger https://v1.pharmanews.devmesh.eu/story/725169/roche-s-genentech-inks-1-5b Rxwire en 2026-09-25T02:52:00Z Roche's Genentech inks $1.5B bispecific pact with fast-rising Earendil https://v1.pharmanews.devmesh.eu/story/725168/adarx-scores-upsized-446m-ipo-while Rxwire en 2026-09-25T02:47:00Z ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plans https://v1.pharmanews.devmesh.eu/story/723331/uchicago-medicine-finaliza-la-fase-de Rxwire en 2026-09-25T02:12:00Z UChicago Medicine finaliza la fase de construcción del Pabellón Oncológico de la Fundación AbbVie, acercando a la realidad una nueva era en la atención del cáncer https://v1.pharmanews.devmesh.eu/story/723163/rnai-drug-specialist-adarx-raises-446m Rxwire en 2026-09-25T00:36:00Z RNAi drug specialist ADARx raises $446M IPO https://v1.pharmanews.devmesh.eu/story/722777/xtalpi-submits-u-s-fda-ind Rxwire en 2026-09-25T00:30:00Z XtalPi Submits U.S. FDA IND Application for KQTD-126, a Potential First-in-Class, Gut-Restricted Pan-TRK Inhibitor for Chronic Intestinal Pain https://v1.pharmanews.devmesh.eu/story/722080/alphabet-and-meta-now-spend-nearly Rxwire en 2026-09-24T22:31:12Z Alphabet and Meta now spend nearly as much on R&D as pharma’s 10 largest drugmakers https://v1.pharmanews.devmesh.eu/story/722079/global-autoimmune-treatment-market-to-reach Rxwire en 2026-09-24T22:15:00Z Global Autoimmune Treatment Market to Reach USD 321.95 Billion by 2034, Driven by Rising Prevalence of Autoimmune Diseases, Growing Adoption of Biologics, and Advances in Precision Medicine Says Maximize Market Research https://v1.pharmanews.devmesh.eu/story/722476/fda-nominee-voices-support-for-vaccines Rxwire en 2026-09-24T21:42:11Z FDA Nominee Voices Support for Vaccines at Senate Hearing Scrutinizing Trump's Moves https://v1.pharmanews.devmesh.eu/story/722075/grail-multicancer-detection-test-wins-fda Rxwire en 2026-09-24T21:08:00Z Grail multicancer detection test wins FDA advisers’ backing https://v1.pharmanews.devmesh.eu/story/722074/muscle-cell-calcium-channel-structure-synchronicity Rxwire en 2026-09-24T21:05:43Z Muscle Cell Calcium Channel Structure, Synchronicity Could Advance Muscle Disease Therapeutics https://v1.pharmanews.devmesh.eu/story/722072/fda-approves-new-option-for-previously Rxwire en 2026-09-24T20:56:41Z FDA Approves New Option for Previously Treated Bile Duct Cancer https://v1.pharmanews.devmesh.eu/story/721878/stat-heidi-overton-trump-s-pick Rxwire en 2026-09-24T08:30:00Z STAT+: Heidi Overton, Trump’s pick for FDA head, to face questions at Senate hearing https://v1.pharmanews.devmesh.eu/story/722071/where-does-fda-nominee-overton-stand Rxwire en 2026-09-24T20:46:00Z Where does FDA nominee Overton stand on vaccines and other key pharma issues? https://v1.pharmanews.devmesh.eu/story/722068/merck-welireg-eisai-lenvima-combo-approved Rxwire en 2026-09-24T20:32:12Z Merck Welireg, Eisai Lenvima combo approved for kidney cancer https://v1.pharmanews.devmesh.eu/story/722066/new-study-highlights-clinical-need-for Rxwire en 2026-09-24T20:30:00Z New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™ https://v1.pharmanews.devmesh.eu/story/722064/stat-fda-commissioner-nominee-heidi-overton Rxwire en 2026-09-24T20:21:32Z STAT+: FDA commissioner nominee Heidi Overton keeps opinions to herself in Senate hearing https://v1.pharmanews.devmesh.eu/story/722063/renibus-therapeutics-announces-participation-at-the Rxwire en 2026-09-24T20:05:00Z Renibus Therapeutics Announces Participation at the Oppenheimer Private Life Sciences Company Showcase https://v1.pharmanews.devmesh.eu/story/722060/jnc-targets-bigger-molecules-with-cellufine Rxwire en 2026-09-24T19:48:59Z JNC Targets Bigger Molecules with Cellufine https://v1.pharmanews.devmesh.eu/story/722059/pfizer-poised-for-gains-with-a Rxwire en 2026-09-24T19:48:10Z Pfizer: Poised For Gains With A New Drug Pipeline And Cost-Cutting Plans https://v1.pharmanews.devmesh.eu/story/722057/fda-commissioner-nominee-overton-rebuffs-questions Rxwire en 2026-09-24T19:36:11Z FDA commissioner nominee Overton rebuffs questions about Trump medical claims https://v1.pharmanews.devmesh.eu/story/722056/the-fda-s-overton-era-and Rxwire en 2026-09-24T19:30:38Z The FDA’s Overton era, and dispatches from Shanghai https://v1.pharmanews.devmesh.eu/story/722055/ac-immune-buy-continued-aci-7104 Rxwire en 2026-09-24T19:21:38Z AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions https://v1.pharmanews.devmesh.eu/story/722054/nsf-funds-iss-national-lab-sponsored Rxwire en 2026-09-24T19:21:00Z NSF Funds ISS National Lab-Sponsored Projects to Advance Applications in Electronics Cooling and Drug Delivery https://v1.pharmanews.devmesh.eu/story/722053/uchicago-medicine-completes-construction-phase-of Rxwire en 2026-09-24T19:07:00Z UChicago Medicine completes construction phase of AbbVie Foundation Cancer Pavilion, bringing new era of cancer care closer to reality https://v1.pharmanews.devmesh.eu/story/724551/why-we-like-starbucks-latest-turnaround Rxwire en 2026-09-24T19:06:08Z Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly https://v1.pharmanews.devmesh.eu/story/721820/fda-adcomm-votes-in-favor-of Rxwire en 2026-09-23T18:23:52Z FDA adcomm votes in favor of benefit-risk of Grail’s cancer test https://v1.pharmanews.devmesh.eu/story/722051/crispr-therapeutics-why-ai-giant-anthropic Rxwire en 2026-09-24T18:59:20Z Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing https://v1.pharmanews.devmesh.eu/story/722050/possible-drug-drug-interactions-flagged-for Rxwire en 2026-09-24T18:59:17Z Possible Drug-Drug Interactions Flagged for Older Americans https://v1.pharmanews.devmesh.eu/story/722049/fda-slams-glp-1-compounder-over Rxwire en 2026-09-24T18:53:03Z FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’ https://v1.pharmanews.devmesh.eu/story/721863/altruist-biologics-preps-for-production-following Rxwire en 2026-09-24T04:29:23Z Altruist Biologics preps for production following EMA GMP certification https://v1.pharmanews.devmesh.eu/story/722046/lilly-again-looks-to-china-for Rxwire en 2026-09-24T18:31:17Z Lilly Again Looks to China for New Drugs, Paying InnoCare $100M to Start R&D Pact https://v1.pharmanews.devmesh.eu/story/722044/nurse-spreads-vaccine-misinfo-md-vs Rxwire en 2026-09-24T18:30:07Z Nurse Spreads Vaccine Misinfo; MD vs PBM; Growing Pains or Red Flags? https://v1.pharmanews.devmesh.eu/story/722042/riaan-s-therapeutic-odyssey-chapter-4 Rxwire en 2026-09-24T18:20:55Z Riaan’s Therapeutic Odyssey – Chapter 4: The Drug Developers https://v1.pharmanews.devmesh.eu/story/721980/senators-grill-fda-nominee-heidi-overton Rxwire en 2026-09-24T14:32:38Z Senators grill FDA nominee Heidi Overton https://v1.pharmanews.devmesh.eu/story/722034/ligand-avencell-ink-financing-deal-worth Rxwire en 2026-09-24T17:17:57Z Ligand, AvenCell ink financing deal worth up to $47M for CAR-T therapies https://v1.pharmanews.devmesh.eu/story/722033/experimental-drug-could-reverse-multiple-sclerosis Rxwire en 2026-09-24T17:16:54Z Experimental Drug Could Reverse Multiple Sclerosis Damage https://v1.pharmanews.devmesh.eu/story/722013/fgfr2-inhibitor-lyrfigtu-wins-fda-approval Rxwire en 2026-09-24T16:00:00Z FGFR2 inhibitor Lyrfigtu wins FDA approval for bile duct cancer https://v1.pharmanews.devmesh.eu/story/722022/cullinan-drops-after-delaying-early-stage Rxwire en 2026-09-24T16:37:46Z Cullinan drops after delaying early-stage trial data for arthritis therapy https://v1.pharmanews.devmesh.eu/story/721956/eli-lilly-s-weekly-insulin-shot Rxwire en 2026-09-24T13:20:58Z Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalry https://v1.pharmanews.devmesh.eu/story/722019/sanofi-healthcare-buys-15-2-stake Rxwire en 2026-09-24T16:14:14Z Sanofi Healthcare buys 15.2% stake in Sanofi India for Rs 1,068 crore https://v1.pharmanews.devmesh.eu/story/722018/the-30-minute-medicine-problem Rxwire en 2026-09-24T16:07:19Z The 30-Minute Medicine Problem https://v1.pharmanews.devmesh.eu/story/721771/another-win-in-igan-as-roche Rxwire en 2026-09-23T16:00:00Z Another win in IgAN as Roche’s sefaxersen hits phase III goal https://v1.pharmanews.devmesh.eu/story/721858/grail-s-galleri-test-wins-endorsement Rxwire en 2026-09-24T00:57:24Z GRAIL's Galleri test wins endorsement from FDA panel https://v1.pharmanews.devmesh.eu/story/722003/lilly-extends-china-innovation-push-in Rxwire en 2026-09-24T16:00:00Z Lilly extends China innovation push in $3.35B Innocare deal https://v1.pharmanews.devmesh.eu/story/722004/n-of-1-therapies-to-address Rxwire en 2026-09-24T16:00:00Z N-of-1 therapies to address rare diseases with no commercial interest https://v1.pharmanews.devmesh.eu/story/722006/regulatory-fda-nods-for-intrabio-nuvation Rxwire en 2026-09-24T16:00:00Z Regulatory: FDA nods for Intrabio, Nuvation, Fempulse, Xenix and more https://v1.pharmanews.devmesh.eu/story/722008/earendil-s-ai-platform-lands-1 Rxwire en 2026-09-24T16:00:00Z Earendil’s AI platform lands $1.5B Genentech collaboration https://v1.pharmanews.devmesh.eu/story/722009/an-instinct-about-atavistik-roche-signs Rxwire en 2026-09-24T16:00:00Z An instinct about Atavistik? Roche signs $1.9B-plus deal https://v1.pharmanews.devmesh.eu/story/722010/awiqli-insulin-this-time-for-lilly Rxwire en 2026-09-24T16:00:00Z Awiqli insulin, this time for Lilly, with FDA-cleared Onswik https://v1.pharmanews.devmesh.eu/story/722012/enveda-raises-a-311m-series-e Rxwire en 2026-09-24T16:00:00Z Enveda raises a $311M series E for pipeline of plant-discovered molecules https://v1.pharmanews.devmesh.eu/story/722014/dme-red-flag-in-merck-brunello Rxwire en 2026-09-24T16:00:00Z DME red flag in Merck Brunello phase III? Surrozen finishes rich https://v1.pharmanews.devmesh.eu/story/722002/grail-sets-new-52-week-high Rxwire en 2026-09-24T15:56:29Z GRAIL sets new 52-week high as FDA panel backs cancer test https://v1.pharmanews.devmesh.eu/story/722001/acrobiosystems-introduces-cho-direct-and-acro Rxwire en 2026-09-24T15:55:00Z ACROBiosystems Introduces CHO-Direct and ACRO AIx to Accelerate AI-driven Drug Discovery https://v1.pharmanews.devmesh.eu/story/721998/marani-health-receives-fda-clearance-for Rxwire en 2026-09-24T15:45:00Z Marani Health Receives FDA Clearance for M•care System, Clearing the Path Toward Commercial Launch https://v1.pharmanews.devmesh.eu/story/721997/acadia-pharmaceuticals-remlifanserin-is-in-trouble Rxwire en 2026-09-24T15:43:46Z Acadia Pharmaceuticals: Remlifanserin Is In Trouble https://v1.pharmanews.devmesh.eu/story/721996/video-on-function-focused-antibody-discovery Rxwire en 2026-09-24T15:37:10Z Video on function-focused antibody discovery workflows with Envisia https://v1.pharmanews.devmesh.eu/story/721994/merck-reveals-study-success-and-possible Rxwire en 2026-09-24T15:34:00Z Merck reveals study success, and possible safety worries, for eye drug hopeful https://v1.pharmanews.devmesh.eu/story/721993/msd-s-dme-drug-could-challenge Rxwire en 2026-09-24T15:32:56Z MSD’s DME drug could challenge anti-VEGF reign, late-stage study suggests https://v1.pharmanews.devmesh.eu/story/721992/fda-panel-narrowly-backs-multi-cancer Rxwire en 2026-09-24T15:32:21Z FDA Panel Narrowly Backs Multi-Cancer Blood Test Despite Doubts It Works https://v1.pharmanews.devmesh.eu/story/721991/roche-secures-separate-discovery-deals-with Rxwire en 2026-09-24T15:30:48Z Roche secures separate discovery deals with Atavistik, Earendil https://v1.pharmanews.devmesh.eu/story/721990/10-year-data-back-early-start Rxwire en 2026-09-24T15:30:23Z 10-Year Data Back Early Start to Biologics in Arthritic Diseases https://v1.pharmanews.devmesh.eu/story/721741/j-j-says-analysis-demonstrates-potential Rxwire en 2026-09-23T14:20:13Z J&J says analysis demonstrates potential of Tecvayli-Darzalex combo for multiple myeloma https://v1.pharmanews.devmesh.eu/story/721989/sarepta-to-pay-regenxbio-39m-to Rxwire en 2026-09-24T15:05:48Z Sarepta to pay Regenxbio $39M to settle gene therapy claims; Vida eyes fourth fund https://v1.pharmanews.devmesh.eu/story/721926/acadia-falls-after-mid-stage-trial Rxwire en 2026-09-24T12:03:08Z Acadia falls after mid-stage trial setback for Alzheimer’s psychosis therapy https://v1.pharmanews.devmesh.eu/story/721982/johnson-county-clintrials-jcct-rebrands-as Rxwire en 2026-09-24T14:45:00Z Johnson County ClinTrials (JCCT) Rebrands as Sequoia Clinical Research https://v1.pharmanews.devmesh.eu/story/721806/astrazeneca-granted-eu-label-expansion-for Rxwire en 2026-09-23T17:50:07Z AstraZeneca granted EU label expansion for COPD therapy, Trixeo in asthma https://v1.pharmanews.devmesh.eu/story/721981/six-reasons-to-register-for-drug Rxwire en 2026-09-24T14:38:28Z Six reasons to register for Drug Discovery Innovators & Investors UK Conference https://v1.pharmanews.devmesh.eu/story/721979/chronic-kidney-disease-market-5-emerging Rxwire en 2026-09-24T14:31:00Z Chronic Kidney Disease Market: 5 Emerging Therapies to Watch as the Treatment Landscape Expected to Evolve by 2036 | DelveInsight https://v1.pharmanews.devmesh.eu/story/721977/arcturus-raised-to-buy-at-citi Rxwire en 2026-09-24T14:26:38Z Arcturus raised to Buy at Citi after mid-stage trial data for liver disease drug https://v1.pharmanews.devmesh.eu/story/721974/acadia-slides-on-phase-2-miss Rxwire en 2026-09-24T14:25:32Z Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward https://v1.pharmanews.devmesh.eu/story/721973/daiichi-sankyo-expands-turbine-collaboration-to Rxwire en 2026-09-24T14:17:00Z Daiichi Sankyo expands Turbine collaboration to accelerate ADC discovery https://v1.pharmanews.devmesh.eu/story/721972/lilly-s-latest-china-drug-deal Rxwire en 2026-09-24T14:14:00Z Lilly’s latest China drug deal; Immunovant’s setback in lupus https://v1.pharmanews.devmesh.eu/story/724549/trump-s-fda-pick-heidi-overton Rxwire en 2026-09-24T14:10:00Z Trump's FDA pick Heidi Overton calls vaccines, mifepristone safe and effective in confirmation hearing https://v1.pharmanews.devmesh.eu/story/721971/elephas-biosciences-and-tes-pharma-collaborate Rxwire en 2026-09-24T14:00:00Z ELEPHAS BIOSCIENCES AND TES PHARMA COLLABORATE TO ADVANCE TRANSLATIONAL RESEARCH FOR LUNG CANCER THERAPY https://v1.pharmanews.devmesh.eu/story/721968/eli-lilly-outlays-3-35bn-for Rxwire en 2026-09-24T13:57:40Z Eli Lilly outlays $3.35bn for secretive drug discovery pact with China’s InnoCare https://v1.pharmanews.devmesh.eu/story/721967/merck-s-experimental-eye-drug-matches Rxwire en 2026-09-24T13:51:12Z Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge https://v1.pharmanews.devmesh.eu/story/721964/novo-nordisk-capital-markets-day-reveals Rxwire en 2026-09-24T13:39:59Z Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine https://v1.pharmanews.devmesh.eu/story/721963/united-therapeutics-sagimet-drop-after-goldman Rxwire en 2026-09-24T13:37:43Z United Therapeutics, Sagimet drop after Goldman Sachs Sell ratings https://v1.pharmanews.devmesh.eu/story/721960/roche-atavistik-bio-partner-on-allosteric Rxwire en 2026-09-24T13:28:56Z Roche, Atavistik Bio partner on allosteric drug discovery https://v1.pharmanews.devmesh.eu/story/721959/kyverna-steps-closer-to-fda-first Rxwire en 2026-09-24T13:27:54Z Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data https://v1.pharmanews.devmesh.eu/story/721958/stat-pharmalittle-we-re-reading-about Rxwire en 2026-09-24T13:21:50Z STAT+: Pharmalittle: We’re reading about the FDA commissioner nominee, a Lilly partnership in China, and more https://v1.pharmanews.devmesh.eu/story/721954/canceriq-deepens-ehr-integrations-to-identify Rxwire en 2026-09-24T13:15:00Z CancerIQ Deepens EHR Integrations to Identify and Guide More Patients Through Cancer Screening, Testing and Surveillance https://v1.pharmanews.devmesh.eu/story/721953/jagsonpal-pharma-to-acquire-group-pharma Rxwire en 2026-09-24T13:14:14Z Jagsonpal Pharma to acquire Group Pharma’s wellness portfolio https://v1.pharmanews.devmesh.eu/story/721952/lilly-s-rival-to-novo-s Rxwire en 2026-09-24T13:11:27Z Lilly's rival to Novo's new Awiqli insulin gets FDA approval https://v1.pharmanews.devmesh.eu/story/721951/glytec-receives-fda-breakthrough-device-designation Rxwire en 2026-09-24T13:06:00Z Glytec Receives FDA Breakthrough Device Designation for Glucommander Pediatrics, an Insulin Management Technology for Hospitalized Newborns and Infants https://v1.pharmanews.devmesh.eu/story/721942/what-j-j-s-spravato-patent Rxwire en 2026-09-24T13:00:00Z What J&J’s Spravato patent win could mean for psychedelic drugs https://v1.pharmanews.devmesh.eu/story/721943/australia-car-t-therapy-and-solid Rxwire en 2026-09-24T13:00:00Z Australia, CAR-T therapy, and solid tumours https://v1.pharmanews.devmesh.eu/story/721947/peer-reviewed-study-published-in-spine Rxwire en 2026-09-24T13:00:00Z Peer-Reviewed Study Published in Spine Open Demonstrates Superior Two-Year Clinical Outcomes for FDA-Approved Synergy Disc® Compared with Cervical Fusion https://v1.pharmanews.devmesh.eu/story/721948/aqua-medical-secures-series-b-funding Rxwire en 2026-09-24T13:00:00Z Aqua Medical Secures Series B Funding to Advance U.S. Pivotal Trial for Novel Through-the-Scope Type 2 Diabetes Procedure https://v1.pharmanews.devmesh.eu/story/721715/anthropic-nvidia-backed-basecamp-research-raise Rxwire en 2026-09-23T13:00:22Z Anthropic-, Nvidia-Backed Basecamp Research Raise $140M Series C Financing Toward Advancing AI-Designed Drugs https://v1.pharmanews.devmesh.eu/story/725940/backed-by-nvidia-basecamp-bags-140m Rxwire en 2026-09-24T12:59:32Z Backed by NVIDIA, Basecamp bags $140M to advance AI-designed drugs https://v1.pharmanews.devmesh.eu/story/721941/fda-advisors-recommend-galleri-multicancer-blood Rxwire en 2026-09-24T12:59:20Z FDA Advisors Recommend Galleri Multicancer Blood Test https://v1.pharmanews.devmesh.eu/story/721940/wuxi-biologics-passes-another-fda-gmp Rxwire en 2026-09-24T12:47:00Z WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability https://v1.pharmanews.devmesh.eu/story/721938/roche-inks-up-to-2b-deal Rxwire en 2026-09-24T12:43:58Z Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs https://v1.pharmanews.devmesh.eu/story/721937/mesoblast-wins-fda-nod-for-new Rxwire en 2026-09-24T12:30:03Z Mesoblast wins FDA nod for new potency assay for Ryoncil https://v1.pharmanews.devmesh.eu/story/721932/l-nutra-marks-10th-anniversary-of Rxwire en 2026-09-24T12:26:00Z L-Nutra Marks 10th Anniversary of Prolon® With a Milestone Year: 136 Patents, 40+ Clinical Trials, and a Series D Investment Round https://v1.pharmanews.devmesh.eu/story/721931/merck-s-return-to-ophthalmology-snags Rxwire en 2026-09-24T12:14:05Z Merck’s return to ophthalmology snags first success https://v1.pharmanews.devmesh.eu/story/721930/lilly-sets-aside-up-to-3 Rxwire en 2026-09-24T12:12:54Z Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare https://v1.pharmanews.devmesh.eu/story/721925/lakewood-amedex-biotherapeutics-announces-first-patient Rxwire en 2026-09-24T12:02:00Z Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers https://v1.pharmanews.devmesh.eu/story/721924/precision-radiation-therapy-alone-doubles-historical Rxwire en 2026-09-24T12:01:00Z Precision Radiation Therapy Alone Doubles Historical Survival Rates for Inoperable Lung Cancer, Landmark Lancet Trial Finds https://v1.pharmanews.devmesh.eu/story/721922/atossa-therapeutics-ceo-dr-steven-quay Rxwire en 2026-09-24T12:00:00Z Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging https://v1.pharmanews.devmesh.eu/story/721917/kyverna-builds-case-for-car-t Rxwire en 2026-09-24T11:58:00Z Kyverna builds case for CAR-T in stiff person syndrome https://v1.pharmanews.devmesh.eu/story/721916/pharma-sector-revenue-to-grow-11 Rxwire en 2026-09-24T11:57:08Z Pharma sector revenue to grow 11-13 pc in FY27 on strong exports, domestic demand: Crisil https://v1.pharmanews.devmesh.eu/story/721913/merck-s-diabetic-macular-edema-therapy Rxwire en 2026-09-24T11:38:00Z Merck’s diabetic macular edema therapy succeeds in Phase 2b/3 trial https://v1.pharmanews.devmesh.eu/story/724548/gsk-slammed-for-grossly-misleading-and Rxwire en 2026-09-24T11:34:00Z GSK slammed for ‘grossly misleading’ and ‘totally unacceptable’ behavior https://v1.pharmanews.devmesh.eu/story/721911/viking-therapeutics-prices-upsized-500m-offering Rxwire en 2026-09-24T11:29:19Z Viking Therapeutics prices upsized $500M offering of common stock and convertible senior notes https://v1.pharmanews.devmesh.eu/story/724547/boehringer-ingelheim-offloads-shanghai-cdmo-to Rxwire en 2026-09-24T11:10:00Z Boehringer Ingelheim offloads Shanghai CDMO to local antibody developer https://v1.pharmanews.devmesh.eu/story/721910/eli-lilly-and-innocare-pharma-agree Rxwire en 2026-09-24T11:09:08Z Eli Lilly and InnoCare Pharma agree on $3.3bn drug research deal https://v1.pharmanews.devmesh.eu/story/721909/lilly-wins-fda-nod-for-once Rxwire en 2026-09-24T11:07:58Z Lilly wins FDA nod for once-weekly insulin product, Onswik https://v1.pharmanews.devmesh.eu/story/721907/lilly-forges-3-35bn-alliance-with Rxwire en 2026-09-24T10:47:35Z Lilly forges $3.35bn alliance with China's InnoCare https://v1.pharmanews.devmesh.eu/story/721905/hll-lifecare-to-expand-pharmacy-network Rxwire en 2026-09-24T10:38:24Z HLL Lifecare to expand pharmacy network to 600 outlets, add 4,500 jobs https://v1.pharmanews.devmesh.eu/story/721904/isotope-refinery-cold-chain-m-a Rxwire en 2026-09-24T10:34:00Z Isotope refinery, cold chain M&A and DARPA deals: pharma finance roundup https://v1.pharmanews.devmesh.eu/story/721901/stat-why-gilead-can-t-stop Rxwire en 2026-09-24T10:30:00Z STAT+: Why Gilead can’t stop talking about its ambitions in immunology https://v1.pharmanews.devmesh.eu/story/721902/what-the-revised-340b-rebate-pilot Rxwire en 2026-09-24T10:30:00Z What the revised 340B rebate pilot programme means for pharma revenue operations https://v1.pharmanews.devmesh.eu/story/721900/from-activity-to-accountability-the-omnichannel Rxwire en 2026-09-24T10:24:02Z From activity to accountability: the omnichannel metrics that pharma leadership actually acts on https://v1.pharmanews.devmesh.eu/story/721897/how-radioligand-therapy-is-rewriting-cancer Rxwire en 2026-09-24T10:18:51Z How radioligand therapy is rewriting cancer care https://v1.pharmanews.devmesh.eu/story/721895/kyverna-says-long-term-data-bolster Rxwire en 2026-09-24T10:02:50Z Kyverna says long-term data bolster FDA submission for rare autoimmune CAR-T https://v1.pharmanews.devmesh.eu/story/721894/enveda-nabs-311m-to-progress-nature Rxwire en 2026-09-24T10:00:39Z Enveda nabs $311m to progress nature-derived drug pipeline https://v1.pharmanews.devmesh.eu/story/721864/innocare-inks-licensing-deal-with-eli Rxwire en 2026-09-24T04:35:44Z InnoCare inks licensing deal with Eli Lilly worth up to $3.35B https://v1.pharmanews.devmesh.eu/story/724545/acadia-misses-mark-in-alzheimer-s Rxwire en 2026-09-24T09:46:00Z Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuing https://v1.pharmanews.devmesh.eu/story/721885/genialis-and-inventia-to-enhance-pancreatic Rxwire en 2026-09-24T09:14:36Z Genialis and Inventia to enhance pancreatic cancer treatment testing https://v1.pharmanews.devmesh.eu/story/724543/otsuka-jv-recalls-one-lot-of Rxwire en 2026-09-24T09:38:00Z Otsuka JV recalls one lot of sodium chloride over labeling issue https://v1.pharmanews.devmesh.eu/story/721886/quotient-sciences-proprietary-ai-enhanced-solution Rxwire en 2026-09-24T09:33:00Z Quotient Sciences proprietary AI-enhanced solution optimises formulation in clinical study https://v1.pharmanews.devmesh.eu/story/721873/basecamp-research-secures-140m-for-ai Rxwire en 2026-09-24T08:29:48Z Basecamp Research secures $140m for AI-driven therapies https://v1.pharmanews.devmesh.eu/story/721881/roivant-reports-top-line-data-from Rxwire en 2026-09-24T08:32:51Z Roivant reports top-line data from IMVT-1402 CLE trial https://v1.pharmanews.devmesh.eu/story/721874/stat-how-a-young-doctor-rose Rxwire en 2026-09-24T08:30:00Z STAT+: How a young doctor rose from rural New Mexico to FDA commissioner nominee https://v1.pharmanews.devmesh.eu/story/721875/stat-in-radiology-ai-is-blurring Rxwire en 2026-09-24T08:30:00Z STAT+: In radiology, AI is blurring the line between technology development and clinical practice https://v1.pharmanews.devmesh.eu/story/721877/stat-trump-boast-on-drug-pricing Rxwire en 2026-09-24T08:30:00Z STAT+: Trump boast on drug pricing policy overstated state-level interest in federal program https://v1.pharmanews.devmesh.eu/story/721880/opinion-stat-a-moment-of-reckoning Rxwire en 2026-09-24T08:30:00Z Opinion: STAT+: A moment of reckoning for preventive cardiology and the precision medicine revolution https://v1.pharmanews.devmesh.eu/story/724542/merck-sees-pivotal-victory-for-3b Rxwire en 2026-09-24T08:15:00Z Merck sees pivotal victory for $3B eye disease prospect https://v1.pharmanews.devmesh.eu/story/721872/podcast-more-meaningful-partnerships-spurring-on Rxwire en 2026-09-24T08:06:54Z Podcast: More meaningful partnerships spurring on Chinese biotechs https://v1.pharmanews.devmesh.eu/story/721871/ec-approves-first-triple-combination-therapy Rxwire en 2026-09-24T08:00:04Z EC approves first triple-combination therapy for asthma maintenance https://v1.pharmanews.devmesh.eu/story/721868/ai-enabled-pharmacovigilance-with-updesh-dosanjh Rxwire en 2026-09-24T07:00:00Z AI-enabled pharmacovigilance, with Updesh Dosanjh https://v1.pharmanews.devmesh.eu/story/721869/biology-chemistry-changing-the-way-drug Rxwire en 2026-09-24T07:00:00Z Biology + chemistry: changing the way drug developers think about innovation and therapeutic design (part I) https://v1.pharmanews.devmesh.eu/story/724541/biogen-springs-social-media-kidney-health Rxwire en 2026-09-24T06:28:00Z Biogen springs social media kidney health campaign with Olympic gymnast Suni Lee https://v1.pharmanews.devmesh.eu/story/724540/novo-s-new-strategy-hinges-on Rxwire en 2026-09-24T06:20:12Z Novo's new strategy hinges on something it can't manufacture: investor trust https://v1.pharmanews.devmesh.eu/story/721866/generic-remedy-crosses-700-franchise-outlets Rxwire en 2026-09-24T06:02:29Z Generic Remedy crosses 700+ franchise outlets across 9 States https://v1.pharmanews.devmesh.eu/story/721860/growth-mode-3-biotechs-that-are Rxwire en 2026-09-24T04:00:00Z Growth mode: 3 biotechs that are staffing up after series B raises https://v1.pharmanews.devmesh.eu/story/724539/lilly-puts-up-100m-plus-billions Rxwire en 2026-09-24T02:39:00Z Lilly puts up $100M, plus billions on the backend, to form 5-target deal with China's InnoCare https://v1.pharmanews.devmesh.eu/story/721859/from-endoscopic-brow-lifts-to-arm Rxwire en 2026-09-24T02:00:00Z From endoscopic brow lifts to arm lifts, how patients are changing their faces and bodies without going fully under. https://v1.pharmanews.devmesh.eu/story/724537/heart-pump-controller-recall-abiomed-removes Rxwire en 2026-09-24T00:00:00Z Heart Pump Controller Recall: Abiomed Removes Automated Impella Controllers https://v1.pharmanews.devmesh.eu/story/721856/grail-s-multi-cancer-blood-test Rxwire en 2026-09-23T22:55:00Z Grail’s Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval https://v1.pharmanews.devmesh.eu/story/721854/menopausal-hormone-therapy-thrombotic-risk-varies Rxwire en 2026-09-23T22:30:00Z Menopausal Hormone Therapy Thrombotic Risk Varies by Dose, Route of Administration https://v1.pharmanews.devmesh.eu/story/721852/stat-nominee-to-lead-fda-aims Rxwire en 2026-09-23T22:14:37Z STAT+: Nominee to lead FDA aims to speed up medical research, combat China’s rise https://v1.pharmanews.devmesh.eu/story/721851/phase-3-data-could-make-roche Rxwire en 2026-09-23T22:09:57Z Phase 3 Data Could Make Roche Drug a Contender to Treat Rare Kidney Disease` https://v1.pharmanews.devmesh.eu/story/721850/arcturus-sees-positive-results-from-mid Rxwire en 2026-09-23T22:04:06Z Arcturus sees positive results from mid-stage trial of RCT-810 in OTC deficiency https://v1.pharmanews.devmesh.eu/story/721849/gilead-hiv-growth-is-not-enough Rxwire en 2026-09-23T21:53:13Z Gilead: HIV Growth Is Not Enough At The Current Price https://v1.pharmanews.devmesh.eu/story/721848/stat-fda-advisory-panel-endorses-grail Rxwire en 2026-09-23T21:47:58Z STAT+: FDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh risks https://v1.pharmanews.devmesh.eu/story/721847/abbvie-revenue-pressure-and-weakening-earnings Rxwire en 2026-09-23T21:40:06Z AbbVie: Revenue Pressure And Weakening Earnings Support A 'Sell'